You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Tyrosine kinases-inhibitor

Showing 1 - 25 of 9,277
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Cancer, HER2 Gene Mutation Trial in Seoul (Neratinib Maleate)

Active, not recruiting
  • Metastatic Cancer
  • HER2 Gene Mutation
  • Neratinib Maleate
  • Seoul, Korea, Republic of
    Korea university Guro hospital
Oct 18, 2023

Tumor Feeding Vessels Deprivation Combined With Tyrosine Kinase

Recruiting
  • Liver Transplant
  • PVHA or TACE
  • Shanghai, Shanghai, China
    The value of tumor feeding vessels deprivation combined with tyr
Nov 26, 2022

Liposarcoma, Metastatic Liposarcoma Trial in Boston, Saint Louis, New York (MGCD516)

Active, not recruiting
  • Liposarcoma
  • Metastatic Liposarcoma
  • Boston, Massachusetts
  • +2 more
Nov 23, 2022

Breast Cancer Trial in Baltimore (Endocrine Therapy and a CDK 4/6 inhibitor)

Recruiting
  • Breast Cancer
  • Endocrine Therapy and a CDK 4/6 inhibitor
  • Baltimore, Maryland
    Johns Hopkins University
Jul 18, 2022

Liver Tumors Trial in Beijing (Tislelizumab plus tyrosine kinase inhibitor)

Recruiting
  • Liver Neoplasms
  • Tislelizumab plus tyrosine kinase inhibitor
  • Beijing, Beijing, China
    302 Hospital
Sep 22, 2023

Acute Lymphoblastic Leukemia Trial in Ann Arbor (Dasatinib, Ponatinib, Berlin-Frankfurt-Münster Chemotherapy)

Recruiting
  • Acute Lymphoblastic Leukemia
  • Ann Arbor, Michigan
    University of Michigan Rogel Cancer Center
Nov 28, 2022

CML Trial in Ciudad Autonoma de Buenos Aire (Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment)

Recruiting
  • CML
  • Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment
  • Ciudad Autonoma de Buenos Aire, Ciudad Autonoma De Buenos Aires, Argentina
    FUNDALEU
Jun 29, 2023

Breast Cancer Trial in Guangzhou (Take probiotics)

Recruiting
  • Breast Cancer
  • Take probiotics
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Mar 6, 2023

Gastrointestinal Stromal Tumors (GISTs) Trial in Seoul (Imatinib Mesylate)

Completed
  • Gastrointestinal Stromal Tumors (GISTs)
  • Imatinib Mesylate
  • Seoul, Korea, Republic of
    Asan Medical Center
Dec 30, 2022

Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Australia, Poland (TG-1701, Umbralisib, Ublituximab)

Active, not recruiting
  • Non Hodgkin Lymphoma
  • Chronic Lymphocytic Leukemia
  • East Melbourne, Victoria, Australia
  • +7 more
Jan 20, 2023

Multiple Sclerosis Trial run by the National Institute of Neurological Disorders and Stroke (NINDS) (tolebrutinib 60mg,

Active, not recruiting
  • Multiple Sclerosis
  • tolebrutinib 60mg
  • tolebrutinib 120mg
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

Lung Cancer, Non Small Cell Lung Cancer Trial in Aurora (Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined))

Not yet recruiting
  • Lung Cancer
  • Non Small Cell Lung Cancer
  • Amivantamab 1050mg
  • +2 more
  • Aurora, Colorado
  • +2 more
Apr 25, 2023

Non Small Cell Lung Cancer, Liquid Biopsy, Tyrosine Kinase Inhibitor Trial in Rotterdam

Recruiting
  • Non Small Cell Lung Cancer
  • +2 more
    • Rotterdam, Netherlands
      Erasmus MC
    Feb 2, 2022

    High-Risk Localized Soft Tissue Sarcoma Trial in Shanghai (Surufatinib, Sintilimab, Radiotherapy)

    Recruiting
    • High-Risk Localized Soft Tissue Sarcoma
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Apr 20, 2023

    Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia

    Not yet recruiting
    • Tyrosine Kinase Inhibitor
    • +2 more
      • Taipei, Taiwan
        National Taiwan University Hospital
      Feb 17, 2022

      Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Positive Trial in New York (Blinatumomab, dasatinib, dexamethasone)

      Recruiting
      • Acute Lymphoblastic Leukemia
      • Philadelphia Chromosome-Positive
      • Blinatumomab
      • +3 more
      • New York, New York
      • +1 more
      Nov 10, 2022

      HRQOL in Locally Advanced Thyroid Carcinoma

      Recruiting
      • Thyroid Cancer
      • +2 more
      • Tyrosine kinase inhibitor drugs.
      • Fuzhou, Fujian, China
        Road Fuma No.420
      Apr 11, 2023

      Primary Membranous Nephropathy Trial (EVER001)

      Not yet recruiting
      • Primary Membranous Nephropathy
      • (no location specified)
      Mar 23, 2023

      Chronic Leukemia Trial in France (Additional biological samples)

      Active, not recruiting
      • Chronic Leukemia
      • Additional biological samples
      • Besançon, France
      • +3 more
      May 31, 2022

      Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia Trial in Houston (Asciminib)

      Recruiting
      • Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia
      • Houston, Texas
        M D Anderson Cancer Center
      Feb 1, 2022

      CNS Lymphoma Trial in Petah Tikva (Imbruvica)

      Recruiting
      • Central Nervous System Lymphoma
      • Petah Tikva, Israel
        Hematology Institute
      May 9, 2022

      GastroEsophageal Cancer, Gastric Cancer Trial in New York (Lenvatinib, Pembrolizumab)

      Recruiting
      • GastroEsophageal Cancer
      • Gastric Cancer
      • New York, New York
      • +1 more
      Aug 12, 2022

      Condition Vasoregulation Function Endothelium in CML Getting TKI

      Recruiting
      • Chronic Myeloid Leukaemia
      • taking blood for the study of biochemical parameters and the study of microcirculation using the method of laser Doppler flowmetry
      • Moscow, Russian Federation
      • +1 more
      Jan 11, 2023

      Diarrhea, Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer Trial in Duarte (other, dietary supplement, drug)

      Active, not recruiting
      • Diarrhea
      • +2 more
      • Laboratory Biomarker Analysis
      • +2 more
      • Duarte, California
        City of Hope Medical Center
      Jun 7, 2022

      Tumor Trial in China, Korea, Republic of, Taiwan (Erdafitinib)

      Active, not recruiting
      • Neoplasm
      • Beijing, China
      • +5 more
      Jan 31, 2023